MedTrace Logo

A Phase 1 Study of PTX-35 in Healthy Volunteers

NCT05116969 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-02-17

No results posted yet for this study

Summary

A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers

Conditions

  • Healthy Volunteer

Interventions

DRUG

PTX-35

PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Sponsors & Collaborators

  • Heat Biologics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-24
Primary Completion
2022-11-29
Completion
2022-11-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116969 on ClinicalTrials.gov